Jay R. Luly, Ph.D., President, Chief Executive Officer and Director of Enanta Pharmaceuticals, Inc. (ENTA), Expects Strong, Competitive Data Set in All-Oral Therapy for HCV Genotype 1 – HedgeChatter

Jay R. Luly, Ph.D., President, Chief Executive Officer and Director of Enanta Pharmaceuticals, Inc. (ENTA), Expects Strong, Competitive Data Set in All-Oral Therapy for HCV Genotype 1

20 Feb

Jay R. Luly, Ph.D., President, Chief Executive Officer and Director of Enanta Pharmaceuticals, Inc. (ENTA), Expects Strong, Competitive Data Set in All-Oral Therapy for HCV Genotype 1

Bystocknews PFE, stock Comments Off

View todays social media effects on PFE

View the latest stocks trending across Twitter. Click to view dashboard

See who Pfizer is hiring next, click here to view

Author